Teva replaces Ranbaxy in making Nexium copy; Novartis selling closed site to university;

> Ranbaxy Laboratories' ongoing quality issues have led the FDA to grant Teva ($TEVA) approval to make a copy of AstraZeneca's ($AZN) blockbuster Nexium. Story

> France is taking action against Chinese antibiotics maker North China Pharmaceutical Group Semisyntech after finding documentation issues in its quality control department. Find the report here

> Solvay announced it will build a new manufacturing and filling facility in the Netherlands to produce hydrogen peroxide to meet demand from the pharma industry. Announcement

> Novartis ($NVS) says it is in exclusive talks with The University of Brighton to sell its former R&D site in Horsham, West Sussex, which was closed last year. Story

> India contract manufacturer Neuland Laboratories says one of its two key manufacturing sites in India has again successfully passed an FDA audit. Release

> Australia's Therapeutic Goods Administration (TGA) has updated guidance, requiring the last manufacturer in the supply chain of a drug to be responsible for certifying the quality before the products are released onto the Australian market. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.